KR102912861B1 - 1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형 - Google Patents
1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형Info
- Publication number
- KR102912861B1 KR102912861B1 KR1020217017514A KR20217017514A KR102912861B1 KR 102912861 B1 KR102912861 B1 KR 102912861B1 KR 1020217017514 A KR1020217017514 A KR 1020217017514A KR 20217017514 A KR20217017514 A KR 20217017514A KR 102912861 B1 KR102912861 B1 KR 102912861B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- perampanel
- cyclodextrin
- pharmaceutical formulation
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779620P | 2018-12-14 | 2018-12-14 | |
| US62/779,620 | 2018-12-14 | ||
| PCT/US2019/066622 WO2020124090A1 (en) | 2018-12-14 | 2019-12-16 | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210107644A KR20210107644A (ko) | 2021-09-01 |
| KR102912861B1 true KR102912861B1 (ko) | 2026-01-15 |
Family
ID=69174604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217017514A Active KR102912861B1 (ko) | 2018-12-14 | 2019-12-16 | 1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12303499B2 (https=) |
| EP (1) | EP3893844A1 (https=) |
| JP (1) | JP7177937B2 (https=) |
| KR (1) | KR102912861B1 (https=) |
| CN (1) | CN113226286B (https=) |
| AU (1) | AU2019395288B2 (https=) |
| BR (1) | BR112021010953A2 (https=) |
| CA (1) | CA3122705A1 (https=) |
| MA (1) | MA54460A (https=) |
| MX (1) | MX2021006317A (https=) |
| WO (1) | WO2020124090A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312284A1 (en) * | 2005-12-21 | 2008-12-18 | Eisai R&D Management Co., Ltd. | Amorphous Form of 1,2-Dihydropyridine Compound |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| HU223945B1 (hu) | 1994-09-27 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények |
| US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| KR100375155B1 (ko) | 1996-05-15 | 2003-08-19 | 화이자 인코포레이티드 | 신규한2,3-이치환된-4(3에이치)-퀴나졸리논 |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
| JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
| DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
| IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| US20100099714A1 (en) * | 2007-03-05 | 2010-04-22 | Eisai R&D Management Co., Ltd. | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases |
| JP2015227288A (ja) | 2012-08-31 | 2015-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | けいれん重積発作の治療用医薬組成物 |
| CN104644592A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种吡仑帕奈药物组合物及其制备方法 |
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| EP4059522A1 (en) * | 2015-02-06 | 2022-09-21 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| CN106389367B (zh) | 2016-11-16 | 2020-12-18 | 杭州朱养心药业有限公司 | 吡仑帕奈包衣片剂药物组合物 |
-
2019
- 2019-12-16 WO PCT/US2019/066622 patent/WO2020124090A1/en not_active Ceased
- 2019-12-16 JP JP2021530970A patent/JP7177937B2/ja active Active
- 2019-12-16 EP EP19839214.4A patent/EP3893844A1/en active Pending
- 2019-12-16 CA CA3122705A patent/CA3122705A1/en active Pending
- 2019-12-16 CN CN201980081856.7A patent/CN113226286B/zh active Active
- 2019-12-16 BR BR112021010953-6A patent/BR112021010953A2/pt unknown
- 2019-12-16 MX MX2021006317A patent/MX2021006317A/es unknown
- 2019-12-16 AU AU2019395288A patent/AU2019395288B2/en active Active
- 2019-12-16 US US17/312,077 patent/US12303499B2/en active Active
- 2019-12-16 KR KR1020217017514A patent/KR102912861B1/ko active Active
- 2019-12-16 MA MA054460A patent/MA54460A/fr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312284A1 (en) * | 2005-12-21 | 2008-12-18 | Eisai R&D Management Co., Ltd. | Amorphous Form of 1,2-Dihydropyridine Compound |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019395288B2 (en) | 2025-04-03 |
| CA3122705A1 (en) | 2020-06-18 |
| JP2022510947A (ja) | 2022-01-28 |
| BR112021010953A2 (pt) | 2021-08-24 |
| US20220023275A1 (en) | 2022-01-27 |
| MA54460A (fr) | 2021-10-20 |
| CN113226286A (zh) | 2021-08-06 |
| KR20210107644A (ko) | 2021-09-01 |
| AU2019395288A1 (en) | 2021-09-23 |
| US12303499B2 (en) | 2025-05-20 |
| MX2021006317A (es) | 2021-08-11 |
| CN113226286B (zh) | 2024-08-20 |
| EP3893844A1 (en) | 2021-10-20 |
| WO2020124090A1 (en) | 2020-06-18 |
| JP7177937B2 (ja) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2343444T3 (es) | Sales de benzodiazepina de actuacion corta y sus formas polimorficas. | |
| CA2943213C (en) | Aripiprazole formulations having increased injection speeds | |
| Ibrahim et al. | Optimization of injectable PLGA in-situ forming implants of anti-psychotic risperidone via Box-Behnken Design | |
| JP6106228B2 (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液 | |
| WO2008148080A2 (en) | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin] | |
| CA2830962C (en) | Otamixaban formulations with improved stability | |
| KR102912861B1 (ko) | 1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형 | |
| TWI740045B (zh) | 難溶性複合物或其溶劑合物、藥物組合物及其應用 | |
| JP6880058B2 (ja) | シクロデキストリン−パノビノスタット付加物 | |
| AU2004236603B2 (en) | Freeze-dried preparation containing methylcobalamin and process for producing the same | |
| KR20130109007A (ko) | 이부프로펜의 주사용 약제학적 조성물 | |
| RU2824582C2 (ru) | Водные фармацевтические составы на основе 1,2-дигидропиридиновых соединений | |
| US20130137739A1 (en) | Solid dispersion comprising triazole compound | |
| JP2025533237A (ja) | 液体ダルババンシン組成物 | |
| Galam et al. | Solid Dispersion: Recapitulation | |
| KR20250133901A (ko) | 베주클라스티닙 제형 | |
| HK1086499A (en) | Freeze-dried preparation containing methylcobalamin and process for producing the same | |
| KR20200061867A (ko) | 도네페질 이온성 액체 및 이의 용도 | |
| NZ616180B2 (en) | Otamixaban formulations with improved stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |